Privo Technologies reports progress in oral cancer trial

Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes

Actinium Pharmaceuticals to reveal ATNM-400 data in NSCLC at AACR-NCI-EORTC International Conference

EiIean Therapeutics to present data on novel wild-type sparing, reversible pan-EGFR inhibitor ZE77-0273

BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL

AstraZeneca strikes landmark drug pricing deal with US Government

Tempus selected by ARPA-H to provide CRO and testing services for ADAPT cancer programme

Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1

C-Ray Therapeutics (Shanghai) presents 225Ac-PSMA-CY313 breakthrough clinical data at EANM 2025

TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences

Sanofi's AlphaMedix meets all primary endpoints in phase 2 study in gastroenteropancreatic neuroendocrine tumours

Aptamer Group wins GBP360,000 contract with global pharmaceutical company for radiopharmaceutical development

Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome

Oncoinvent reports positive final Phase 1 results for Radspherin in ovarian cancer trial

Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation